Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (1): 93-100.doi: 10.12092/j.issn.1009-2501.2023.01.012

Previous Articles     Next Articles

Role of the m7G methyltransferase METTL1 in tumours

HONG Ziqiang1,3, GOU Wenxi2, CUI Baiqiang1,3, BAI Xiangdou1,3, JIN Dacheng3, GOU Yunjiu3   

  1. 1The First Clinical Department of Gansu University of Traditional Chinese Medicine, Lanzhou 730000, Gansu, China; 2Southern Medical University, Guangzhou 510515, Guangdong, China; 3Department of Thoracic Surgery, Gansu Provincial Hospital, Lanzhou 730000, Gansu, China
  • Received:2022-09-20 Revised:2022-11-27 Online:2023-01-26 Published:2023-02-14

Abstract:

N7-methylguanosine (m7G) is a common post-transcriptional modification of RNA that plays an important role in RNA processing, metabolism and function and is mainly regulated by the methyltransferase 1 (METTL1) and WD repeat domain 4 (WDR4) complexes. Several studies have shown that the METTL1/WDR4 complex promotes or inhibits the progression of many tumours, including head and neck tumours, lung, liver, colon, bladder and esophageal squamous cancers, which are dependent on m7G methylation modification of tRNA or miRNA. Therefore, METTL1 and m7G modification can be used as biomarkers or potential intervention targets, providing a new direction for early diagnosis and treatment of tumors. This article will mainly discuss the mechanism and corresponding research progress of METTL1 in tumorigenesis through m7G.

Key words: epigenetic modification, RNA methylation, m7G, METTL1, tumor

CLC Number: